CytomX’s Late-Line CRC Program Draws Focus at Morgan Stanley

CytomX Therapeutics (CTMX) highlighted its late-line colorectal cancer (CRC) program, Varseta-M, as a key focus at Morgan Stanley’s 24th Annual Global Healthcare Conference, where analysts and investors scrutinized its clinical progress and financial positioning. The company’s antibody-drug conjugate, targeting EpCAM, demonstrated response rates of 20% to 30% in fourth-line or later CRC patients, exceeding benchmark third-line standards of 1% to 2% response rates. Progression-free survival estimates for Varseta-M ranged from 6 to 7 months, aligning with the broader fourth-line CRC market, which could exceed $1 billion annually in the U.S., where about 40,000 patients progress to third-line or later treatment stages. However, safety concerns—particularly grade 3 diarrhea rates that initially spiked to 30% before mitigation—remain a critical hurdle. Dual prophylaxis with loperamide and budesonide reduced this risk to around 10%, aligning with CytomX’s target acceptable range of 10% to 20% for tolerability.